Evaluate the Effects of GPI 1485 on Erectile Function Following Bilateral Nerve-Sparing Prostatectomy

PHASE2CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

December 31, 2003

Conditions
ImpotenceProstate Cancer
Interventions
DRUG

GPI 1485

Trial Locations (25)

10016

NYU Urology Associates, New York

10017

Memorial Sloan-Kettering Cancer Center, New York

10032

Columbia University, New York

21287

Johns Hopkins Hospital, Baltimore

27710

Duke University Medical Center, Durham

28204

Carolinas Health Care System McKay Urology, Charlotte

29572

Carolina Urologic Research Center, Myrtle Beach

44195

The Cleveland Clinic Foundation, Cleveland

48202

Henry Ford Health System, Vattikuti Institute for Urology, Detroit

63110

Washington University School of Medicine, St Louis

63141

PPS Clinical Research, St. Louis, St Louis

70112

Tulane University Health Sciences Center, New Orleans

85032

HOPE Research Institute, LLC, Phoenix

91942

Center for Urological Research, La Mesa

98101

Virginia Mason Medical Center, Seattle

94305-5118

Stanford University Medical Center, Stanford

06106

Connecticut Surgical Group, Hartford

06052-1395

Connecticut Urological Research at Grove Hill, New Britain

48109-0330

University of Michigan, Ann Arbor

07601

Hackensack University Medical Center, Hackensack

17604-3200

Urological Associates of Lancaster, Ltd., Lancaster

37232-2765

Vanderbilt Medical Center, Nashville

77030-4009

The University of Texas MD Anderson Cancer Center, Houston

78229-3900

The University of Texas Health Science Center at San Antonio, San Antonio

98431-1100

Madigan Army Medical Center, Tacoma

All Listed Sponsors
collaborator

Symphony Neuro Development Company

INDUSTRY

lead

Eisai Inc.

INDUSTRY

NCT00090376 - Evaluate the Effects of GPI 1485 on Erectile Function Following Bilateral Nerve-Sparing Prostatectomy | Biotech Hunter | Biotech Hunter